Metformin.

Metformin interferes with the calcium dependent uptake of the intrinsic factor B12 complex at the ileal receptor. Long term use lowers circulating B12, which is why status is normally monitored.

The ileal receptor that binds the intrinsic factor B12 complex needs calcium, and metformin disturbs that calcium dependent membrane step. Supplemental calcium restores the uptake.

When B12 falls the folate cycle stalls at the methyl form and homocysteine rises. Active folate keeps that arm of the cycle supplied while B12 is being addressed.

Berberine inhibits mitochondrial complex I and activates AMPK, the same broad mechanism metformin uses. Effects on glucose handling and on gastrointestinal tolerance both add together.

Lipoic acid activates AMPK and promotes GLUT4 movement to the cell surface. It acts on the same signalling node from a different direction.

Inositol phosphoglycans act as second messengers downstream of the insulin receptor. Metformin acts mainly on hepatic glucose output, so the two work at different points of the same handling of blood sugar.

D-chiro-inositol supports the glycogen synthesis arm of insulin signalling inside the cell. That is downstream of where metformin acts, so the two are complementary.

Magnesium is required by the tyrosine kinase activity of the insulin receptor and by many ATP dependent steps. Adequate magnesium supports the same glucose handling metformin influences.

Deoxynojirimycin slows the intestinal breakdown of starch into absorbable glucose. That works before absorption, where metformin works after it, so the mechanisms do not overlap.

Viscous fibre delays gastric emptying and flattens the rate of glucose entering the blood after a meal. It also compounds the gastrointestinal fullness metformin can cause.

Gymnemic acids interfere with glucose transport across the intestinal wall and blunt sweet taste signalling. This acts on intake and absorption rather than on hepatic output.

Several 2026 trials tested multi-strain probiotics alongside metformin and reported fewer gastrointestinal complaints and changes in anthropometric and metabolic measures compared with metformin alone. Part of metformin's action runs through the gut microbiome and bile acid pool, which is the proposed point of contact. Anyone taking a prescribed medicine should have any addition reviewed by their prescriber.

A trial of Bifidobacterium animalis subsp. lactis BLa80 reported changes in glycaemic markers and gut microbiota composition in the supplemented group. Glycaemic markers are markers, not clinical outcomes. Strain-specific findings do not transfer to other bifidobacteria.

Saccharomyces boulardii has the widest evidence base of any probiotic for loose stools during medication courses. Metformin's most common early complaint is gastrointestinal, and bacterial multi-strain products have been tested for it directly. The extension to this yeast is reasoning by class rather than a tested pairing.

Homocysteine is remethylated either by methionine synthase, which needs vitamin B12 and 5-methyltetrahydrofolate, or by betaine homocysteine methyltransferase, which uses betaine. When the B12 dependent route is limited, the betaine route carries more of the load. That two-route arrangement is settled biochemistry and is why betaine appears in formulas built around methylation.

Metformin is a substrate for OCT1, OCT2 and the multidrug and toxin extrusion transporters, and thiamine moves through overlapping cation transport systems including THTR-2. Competition at a shared carrier is a recognised class of interaction. The clinical size of that competition in people has not been quantified, so read it as mechanistic.

A 2025 systematic review and meta-analysis assessed chromium supplementation in women, with metformin used as background care in several of the included trials, reporting effects on insulin and glucose indices. Those are markers rather than clinical outcomes. Because both point the same direction on glucose markers, the combination is additive rather than complementary, and additive glucose lowering in someone on prescribed medication is a conversation for the prescriber.

Metformin's primary molecular action is partial inhibition of complex I, which passes electrons to ubiquinone. Coenzyme Q10 is co-formulated on the reasoning that the downstream carrier supports the chain. No human study has shown that supplemental coenzyme Q10 changes anything about metformin's effect, so this is a mechanistic proposal.

Psyllium forms a gel that flattens the post-meal glucose curve, an effect reproduced across many trials, and the same gel can delay the absorption of medicines taken at the same time. Separating a viscous fibre from an oral medicine by a couple of hours is standard dispensing practice for that reason. Both directions of the interaction matter here.

A 2026 study reported that the prolactin-lowering effect of metformin differed by baseline vitamin D status in the participants studied. Prolactin is an endocrine marker, and the finding is an effect modification within one cohort rather than a demonstrated benefit of combining the two. It is worth flagging because vitamin D status is common background variation in anyone taking metformin.

Riboflavin becomes FMN, the flavin prosthetic group of complex I itself, and FAD for complex II and the acyl-CoA dehydrogenases. That cofactor requirement holds regardless of metformin. It is established biochemistry rather than an interaction finding.

Methionine synthase requires both 5-methyltetrahydrofolate as methyl donor and methylcobalamin as cofactor; when the cobalamin side is limited, folate becomes trapped as the methyl form and cannot re-enter other one-carbon reactions. That methyl folate trap is textbook biochemistry. It is why folate status alone does not describe the picture where B12 status is falling.

Zinc, iron and copper compete for shared divalent metal transport at the enterocyte, so mineral stacks affect one another regardless of any medicine present. This matters for anyone assembling a nutrient regimen around a prescription. The competition is established absorption pharmacology.